Strategic Initiative

Slingshot members are tracking this corporate initiative:

Advaxis (ADXS) Announces Out-Licensing Deal of Lm-Based Antigen Delivery Technology with SELLAS to Develop a Novel Cancer Immunotherapy Agent

Source Link:
http://www.prnewswire.com/news-releases/advaxis-and-sellas-announce-licensing-agreement-for-development-of-wt1-antigen-targeting-immunotherapy-300413536.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ADXS
100%
SELLAS Life Sciences Group
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Strategic Initiative Date
Announcement Date:
Feb 27, 2017
Projected Implementation:
Q1, 2017
Relevance Tracked Until:
Q1, 2019
Related Projects Image

  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Out-licensing, Lm-based Antigen Delivery Technology, Immunotherapy Agent, Galinpepimut-s
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.